top of page
Search

Positive Initial Results from Phase 1 Study of COVID-19 antiviral therapy

  • ju5997
  • Mar 12, 2021
  • 1 min read

Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, and its collaborator Novartis, today announced initial results from its ongoing phase 1 study of its first tri-specific COVID-19 antiviral treatment, ensovibep (MP0420), in healthy volunteers.






















































 
 
 

Comments

bottom of page